GABA-A Variant (GABRA1/GABRG2)

About Grann Pharmaceuticals

Grann Pharmaceuticals is a private, pre-clinical stage biotech leveraging mRNA-LNP technology to address diseases caused by genetic mutations and protein deficiencies. Its pipeline includes programs for obesity/NAFLD, GABA-A variants, Rett syndrome, and colorectal adenocarcinoma, with a core technological focus on engineering LNPs capable of crossing the blood-brain barrier for CNS applications. Founded and led by CEO Thomas Lyle Temple, the company is motivated by a personal legacy and operates as a pre-revenue entity advancing its research toward human trials.

Therapeutic Areas